Thawing fluid, preparation method therefor and use thereof

US12543727B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12543727-B2
Application numberUS-202017594345-A
CountryUS
Kind codeB2
Filing dateMar 2, 2020
Priority dateApr 9, 2019
Publication dateFeb 10, 2026
Grant dateFeb 10, 2026

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A thawing solution has 0.1-50 g of a biomimetic material for controlling ice, 0-1.0 mol L −1 of a water-soluble sugar, and balance of a buffer solution. The biomimetic material for controlling ice is a material for controlling ice having an ice-philic group and a hydrophilic group. The hydrophilic group is a functional group that can form a non-covalent interaction with water molecules, and the ice-philic group is a functional group that can form a non-covalent interaction with ice. Using the thawing solution and the thawing reagent prepared from the biomimetic material for controlling ice, which material has ice-philic and hydrophilic properties, the growth and recrystallization of ice crystals can be effectively controlled, and damage to cells or tissue caused by uncontrolled growth of the ice crystals during recovery can be significantly ameliorated.

First claim

Opening claim text (preview).

The invention claimed is: 1 . A thawing solution comprising, per 100 mL: 0.1-50 g of a biomimetic ice growth inhibition material, a water-soluble saccharide at 0-1.0 mol L −1 and a balance of a buffer, wherein the biomimetic ice growth inhibition material is an atactic polyvinyl alcohol (PVA) having a syndiotacticity of 45%-65% and a molecular weight of 10 kDa-500 kDa, or a combination of said PVA with an amino acid, or with a polypeptide, or with a polyamino acid. 2 . The thawing solution according to claim 1 , wherein the amino acid is selected from one of or a combination of two or more of arginine, threonine, proline, lysine, histidine, glutamine, aspartic acid, and glycine; and/or the polyamino acid is a homopolymer of at least one selected from lysine, arginine, proline, threonine, histidine, glutamic acid, aspartic acid, and glycine; and/or the polypeptide is one or two or more of L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT), L-Ala-L-Ala-L-Thr (AAT) or L-Thr-L-Cys-L-Thr (TCT); and/or the PVA has a degree of hydrolysis of 80%-99%, 82%-87%, 87%-89%, 89%-99% or 98%-99%. 3 . The thawing solution according to claim 1 , wherein the content of the biomimetic ice growth inhibition material is 1.0-30 g; or the biomimetic ice growth inhibition material comprises 1.0-6.0 g of the PVA; or the biomimetic ice growth inhibition material comprises 1.0-30 g of the amino acid; or the biomimetic ice growth inhibition material comprises 0.1-9.0 g of the polyamino acid; or the biomimetic ice growth inhibition material comprises 1.0-13 g of the polypeptide; or the biomimetic ice growth inhibition material is a combination of the PVA with the amino acid, the polypeptide and/or the polyamino acid. 4 . The thawing solution according to claim 3 , wherein the amino acid is a combination of arginine and threonine. 5 . The thawing solution according to claim 4 , wherein the water-soluble saccharide is selected from sucrose, trehalose, a water-soluble cellulose and a polysucrose. 6 . The thawing solution according to claim 1 , wherein the water-soluble saccharide is at least one of a non-reducing disaccharide, a water-soluble polysaccharide and a glycoside; and/or the buffer is selected from at least one of DPBS, hepes-buffered HTF buffer and other cell buffers. 7 . The thawing solution according to claim 1 comprising, wherein the PVA has a syndiotacticity of 50%-55% and a molecular weight of 13 kDa-23 kDa.

Assignees

Inventors

Classifications

  • Temperature processes, e.g. following predefined temperature changes over time · CPC title

  • A01N1/125Primary

    Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators · CPC title

  • A01N1/12Primary

    Chemical aspects of preservation · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12543727B2 cover?
A thawing solution has 0.1-50 g of a biomimetic material for controlling ice, 0-1.0 mol L −1 of a water-soluble sugar, and balance of a buffer solution. The biomimetic material for controlling ice is a material for controlling ice having an ice-philic group and a hydrophilic group. The hydrophilic group is a functional group that can form a non-covalent interaction with water molecules, and th…
Who is the assignee on this patent?
Univ Peking Third Hospital, Inst Chemistry Cas
What technology area does this patent fall under?
Primary CPC classification A01N1/125. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).